CEO, BiVictrix Therapeutics

Tiffany Thorn is the Founder of BiVictriX Therapeutics plc and is the inventor of the Bi-Cygni® approach, a novel concept which originated from her previous experience as a clinician supporting the diagnosis of haematological malignancies. Ms Thorn has led BiVictriX since its formation in 2016, meeting key corporate milestones and securing c.£10m in investment to date, including leading the successful IPO of the Company onto the London Stock Exchange’s AIM market in August 2021. Ms Thorn trained and qualified as a HCPC-registered Clinical Immunologist at Manchester Royal Infirmary and Preston Royal Hospital, UK and during this time was awarded “NHS England’s Chief Scientific Officer’s Rising Star Award” for her commitment to facilitating better healthcare by strengthening the links between the UK’s healthcare sector and the biotech industry. Ms Thorn graduated with a First-Class Honours Degree in Biochemistry with Biomedicine from Lancaster University and obtained an MSc in Clinical Immunology from the University of Manchester.